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Background: There is a general lack of recommendations for and basic information tailored at 
sexologists and other health care professionals for when they encounter trans people in their 
practice. 
Aim: We present to clinicians an up-to-date overview of clinical consensus statements on trans 
health care with attention for sexual function and satisfaction. 
Methods: The task force consisted of 7 clinicians experienced in trans health care, selected among 
ESSM scientific committee. Consensus was guided by clinical experience and a review of the 
available literature and by interactive discussions on trans health, with attention for sexual function 
and satisfaction where available.  
Outcomes: The foci of the paper are assessment and hormonal aspects of trans health care. 
Results: As the available literature for direct recommendations was limited, most of the literature 
was used as background or indirect evidence. Clinical consensus statements were developed based 
on clinical experiences and the available literature. The results are divided into 6 sections 1) general 
statements and statements on 2) assessment of children and adolescents, 2) assessment of adults, 
3) hormone therapy in trans assigned female at birth and 4) assigned male at birth people and 5) 
sexual functioning and satisfaction in relation to surgical treatment. 
Clinical Implications: With the multiple barriers to care that many trans people experience, basic 
care principles still need to be stressed. We recommend that health care professionals (HCPs) 
working with trans people recognise the diversity of genders, including male, female and non-
binary individuals. Also, HCPs assessing gender diverse children and adolescents should take a 
developmental approach that acknowledges the difference between prepubescent gender diverse 
children and pubescent gender diverse adolescents and trans adults. Furthermore, trans people 
seeking gender affirming medical interventions should be assessed by HCPs with expertise in trans 
health care and gender affirming psychological practice. If masculinisation is desired, testosterone 
therapy with monitoring of serum sex steroid levels and signs of virilisation is recommended. 
Similar, if feminisation is desired, we recommend estrogens and/or anti-androgen therapy with 
monitoring of serum sex steroid levels and signs of feminisation. HCPs should be aware of the 
influence of hormonal therapy on sexual functioning and satisfaction. We recommend HCPs are 




Strengths & Limitations: This is an up-to-date ESSM position statement. These statements are 
based upon the data that is currently available, however it is vital to recognise that this is a rapidly 
changing field and that the literature, particularly in the field of sexual functioning and satisfaction 
is limited. 
Conclusion: This ESSM position statement provides relevant information and references to 
existing clinical guidelines with the aim of informing relevant healthcare professionals on best 
practices when working with transgender people. 
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In view of the recent change in the clinical diagnosis use in transgender health in the new edition 
of the WHO International Classification of Disease (ICD-11)[1], this position statement aims to 
provide clinical advise to European sexologists and health care professionals (HCPs) who may 
encounter trans people in their clinical practice. Although international guidelines for the care of 
trans people exist, such as the Standards of Care developed by the World Professional Association 
for Transgender Health (WPATH)[2] or the Endocrine Society guidelines[3], they require updating 
due to the important change in the classification system that most European Health services will 
be using. The newly accepted diagnosis “Gender Incongruence” (GIC) has been moved out of the 
mental health chapter in the new edition of the ICD (ICD-11). This is an important change in the 
classification system that it hopes to depathologize trans people. The change in the ICD-11 
questions the need of mental health professionals as part of the assessment of trans people wishing 
gender affirming medical interventions (GAMI). This paper is a Position Statement by the 
European Society for Sexual Medicine (ESSM) that provides clinicians working with trans people 
an up-to-date overview of trans health care in general and discuss the effect of GAMI in sexual 
function and satisfaction where evidence is available. There is an enormous variation of services 
working with trans people in Europe, from very well developed multi-disciplinary services to single 
individuals working independently. It is expected that by reading this document, European health 
care professionals and sexologists will increase the knowledge about trans health. This paper aims 
to provide information and up to date references to existing clinical guidelines that would make 
access to more specialised information easily available.  
In this paper, the term “trans” is used as a short form, which is intended to take into account people 
whose gender identity does not (or not completely and/or permanently) match their sex assigned at 
birth. The adjective trans thus encompasses both trans binary people, who identify as women or 
men, as well as gender non-binary people who identify as neither (exclusively) male nor female. 
This latter group includes, but is not limited to, those who experience not having a gender identity 
(agender), or as having a gender identity that is changing and shifting over time (genderfluid or 
genderflux). Gender identity is defined as the psychological identification of oneself or the internal 
sense of being in relation to gender.[4] It is important to highlight that the term trans does not 




trans people undergo Gender Affirming Medical Intervention (GAMI), such as hormonal therapy, 
surgeries or other interventions but others do not desire these. Where necessary, the distinction is 
made between assigned male at birth (AMAB) and assigned female at birth (AFAB) trans people. 
When studies are cited, we will use ‘trans AFAB people’ and ‘trans AMAB people’ when these 
studies did not include information of the self-identified identity labels of the respondents. In most 
of these studies, respondents were classified by the authors themselves as trans men or trans women 
merely based on their assigned sex at birth, hereby ignoring the existence of gender non-binary 
trans people.  
Methodology 
The position statement is divided into six main sections (general statements, assessment of children 
and adolescents, assessment of adults, hormone treatment in both trans AFAB and AMAB people, 
and surgical interventions). The aim was not to undertake a systematic literature review in every 
single section. The authors of this position statement are ESSM members actively involved in the 
clinical care of adolescent and adult trans people in Europe. They were selected by the ESSM 
scientific committee based on their long standing clinical experience and scientific involvement in 
the specific areas of trans health. They had all published literatures reviews in their specific areas 
of expertise, or are/were part of the development of international guidelines. The disciplines 
involved are endocrinology, psychology, psychiatry, plastic/gender surgery, and sociology. The 
ESSM funded two face-to-face meetings but no further financial support was received for this 
work.  
In 2018, a review of recent literature took place using the following words: for terms referring to 
transgender people (transsexualism, transgender, gender dysphoria, gender identity disorder, 
trans*, gender incongruence), for assessment (assessment, counselling, gender development, 
mental health, sexual function, sexual desire, sexual activity, sexual satisfaction), for hormonal 
treatment, (cross-sex hormones, testosterone, estrogen, blockers, GnRH agonist), for surgery 
(gender affirming surgery, gender confirming surgery, sex reassignment surgery, mastectomy, 
hysterectomy, ovariectomy, metaidoioplasty, phalloplasty, erection prostheses, orchiectomy, 
vulvoplasty, vulvo-vaginoplasty, vaginoplasty, breast augmentation). Every term used for 




for hormonal treatment, surgical interventions.  Literature research was conducted on PubMed, 
PsychINFO, Embase, and Scopus. from January 1, 1996 up to 2018 were included. It is important 
to acknowledge that the recommendations were consensus based and supported by the background 
literature. A literature search was carried out to determine whether there were any studies 
(published from January 1996 to April 2018) unknown to the authors that might be relevant to this 
position paper. The existing knowledge and selected literature was interactively discussed among 
the authors based on their clinical expertise and bringing in different disciplinary knowledge. The 
foci of the paper are assessment and hormonal aspects of trans health care, while the surgical 
options are only introduced. In addition, the selected literature of the impact of hormonal treatment 
and surgery on sexual functioning and sexual satisfaction was summarised. The literature as well 
as the clinical experience of the panel was used to develop the statements. The available literature 
for a direct recommendation was limited and most of the literature was used as background or 
indirect evidence. When a statement was not approved by all, it was re-written until consensus was 
reached. Each statement had to be approved by all the authors in order to be accepted. Furthermore, 
in view of the limitation on the amount of references allowed in this manuscript, each author 
selected the most relevant publications that will support the clinical consensus statements. 
General statements 
Statements 
1. We advise that HCPs when working with trans people recognise the diversity of genders, 
including male, female and non-binary individuals. 
2. We advise that HCPs when working with trans people openly ask for the individual gender 
experience of the person seeking treatment, including which pronouns and name they like 
to be addressed with, and recognise this may change in the future.  
3. We advise that HCPs when working with trans people critically reflect upon discriminatory 
factors influencing both access to and outcomes of gender-related health care services, and 
make the necessary changes to accommodate all trans individuals.  
4. We advise that HCPs when working with trans people should critically reflect on their own 




5. We advise that HCPs when working with adults trans people should explain the result of 
the clinical assessment with the aim of a shared understanding and shared responsibility.  
Evidence 
The traditional notion of the gender binary has been shaken due to empirical findings of the last 10 
years. Large-scale online surveys provide information on the extent to which trans people either 
find themselves identifying with a gender within or beyond the binary. In an online study in the 
USA with 6,436 trans participants, only 67% of the participants stated identifying within the gender 
binary, 33% stated having another gender identity.[5] In a recent European large-scale survey, 
similar results of 20% up to 36% of trans people identifying beyond a binary gender (e.g., agender, 
gender non-binary, genderflux, …) were found.[6] Modern gender theories are based on these 
recent empirical findings and assume a variety of gender identities, with people identifying as male 
or female, to people who have a gender which is neither male nor female and may identify as both 
male and female at one time, as different genders at different times, as no gender at all, or dispute 
the very idea of any or only two genders.[7] A professional attitude should be characterised by 
respect and acceptance for this variety of gender identities, based on the knowledge that gender 
identity is very personal and only the individual knows this.  
Trans people should be addressed with their desired pronouns and names. The request to use 
diverse pronouns (e. g., they) or the rejection of pronouns (e. g., for persons who identify gender-
neutral or agender) should be taken just as seriously as the request of pronouns for women or men 
(e. g., for persons who identify as female or male). Since names and preferred pronouns, as well as 
gender experiences, may change in the course of a treatment, such changes should be taken into 
account.[8] Using the person’s chosen name is associated with lower depression, suicidal ideation, 
and suicidal behaviour.[9] 
In their everyday lives trans people often share the experience of social exclusion, lack of (legal) 
gender recognition, discrimination and stigmatisation, similar to members of other sexual or gender 
minorities. Rejection, non-affirmation, and victimization are strongly related to suicidal ideation 
through experiences of internalized transphobia and negative expectations.[10] The risk of minority 
stress and its severe implications is increased if further disadvantageous features are present such 
as a low socioeconomic status, physical and/or mental health issues, physical or mental disability, 




access to, and experiences with, trans health care services.[12] Furthermore, the increasing social 
protection of sexual and gender minorities against discrimination and exclusion plays an important 
role on the way to a better health of trans people.  
The way in which relationships are formed in the health care of trans people is of central 
importance. In order to ensure a needs-based, flexible and individualised health care for sexual and 
gender minorities, HCPs should reflect on their own understandings of sex and gender.  
Values 
The evidence regarding the prevalence of and diversity in trans populations is consistent but 
limited, possibly implying care services are currently insufficient. Being respectful to trans people 
is paramount for any health care professional working with this population. In addition, 
understanding the vulnerabilities of some trans people may help when developing a client-centred 
treatment plan. 
Remarks 
Until recently, most evidence found is based on binary conceptions of transgender experiences, 
overlooking the gender diversity within the trans population. A European approach in the 
acquisition of inclusive prevalence data is timely, stressing the responsibility of European 
institutions and national governments to support this research. The organisation of trans health care 
will largely benefit from and be affected by this information.  
Assessment of gender diverse children and adolescents  
Statements 
6. We advise that HCPs assessing gender diverse children and adolescents support the 
exploration and expression of the youth’s experienced gender and help to reduce 
experienced barriers for those seeking care. 
7. We advise that HCPs assessing gender diverse children and adolescents take a 




more open to change in prepubescent gender diverse children compared to pubescent 
gender diverse adolescents and adults. 
8. We advise that HCPs assessing gender diverse children and adolescents assess resilience 
and vulnerabilities, and treat (or refer for treatment) possible mental health problems. 
9. We advise that HCPs assessing gender diverse children and adolescents support parents 
and/or legal guardian and school and other important social networks (when possible) to 
provide a safe and accepting home and school environment. 
10. For prepubescent gender diverse children who desire to live in a role consistent with their 
experienced gender identity, we advise the HCPs advise that parents and the social 
environment consider social transitioning of the child after discussing the pros and the cons 
and while providing continuous psychological support. 
11. For pubertal gender diverse adolescents, we advise that HCPs inform and explore all non-
medical and medical options, including the effect that GAMIs (puberty blockers, hormones 
as well as surgical) may have on sexuality and fertility and if indicated, facilitate GAMIs. 
12. In countries requiring an assessment process including a clinical diagnosis in order to access 
Gender Affirming Medical Intervention (GAMI), we advise that HCPs assessing trans 
adolescents for GAMI have the expertise in reaching the required diagnosis for their health 
service. 
Evidence 
Trans care clinics for youth have seen a sharp increase in referrals and interest over the last decades, 
reflecting the recognition that young children and adolescents can experience gender diversity and 
that children and families seek support.[13] Access to this sort of care is a serious concern in large 
parts of the world where there is still much stigma around gender diversity.  
An important distinction between the age groups is that in many prepubescent gender diverse 
children the incongruence between birth assigned gender and experienced gender will remit before 
puberty although some criticise the follow-up studies with this finding.[14] Especially for 
prepubescent children who are not yet in need of medical interventions, it is therefore argued that 
a diagnosis of GIC should be removed from the classification systems.[15] However, at present, 




With regard to psychological functioning, gender diverse children and adolescents show higher 
rates of emotional and behavioural problems (depression, anxiety, suicidality, autism) than norm 
populations.[17-19] There is some evidence that youth who grow up in supportive environments 
that allow social transitioning and provide access to GAMI, may experience less distress.[20, 21] 
Other studies show a link between peer acceptance/poor peer relations, victimisation and mental 
health problems.[22, 23] Acceptance at home and at school is therefore important for the well-
being of gender diverse children and adolescents.[23] Acceptance entails that the child is provided 
with enough space to explore gender diverse feelings on a continuous basis, without the 
expectations of a singular developmental pathway. This also includes exploring sexuality, and 
sexual relationships, as they in turn might shape gender identity processes.[24, 25] 
For pubescent gender diverse adolescents, GAMI including puberty suppression as part of a 
broader approach with mental health support is helpful to reduce the distress accompanying the 
incongruence between physical (growing) sex characteristics and experienced gender.[21] 
Evidence for the effectiveness of this approach comes from studies that initiated pubertal 
suppression in trans adolescents after a careful assessment regarding the following; a) the 
adolescents shows a persistent and long lasting GIC that usually intensified or began around the 
start of puberty (and did not remit), b) the adolescents’ co-occurring psycho-social difficulties 
should not interfere or hamper assessment or treatment, c) the adolescent understands the pros and 
cons of GAMI and has sufficient capacity to give informed consent, d) the adolescent has sufficient 
family or other social support to pursue GAMI, and e) the adolescent has actually experienced of 
the first physical pubertal changes (Tanner stage G2) since blocking is not necessary before that 
time and the experience of puberty is deemed important for gender identity development.[21] 
It has been argued that as many health services globally require a diagnostic term to have access to 
health services, a diagnosis has been left in both classifications. Both the revisions of the diagnostic 
criteria of ‘gender dysphoria’ (GD) in the DSM-5 and of ‘gender incongruence’ (GIC) in the ICD-
11 aim at extending the scope to include non-binary trans people.[1, 26] Gender identities or 
experiences that are outside the gender binary (men and women) are explicitly recognised for the 
first time (“alternative gender different from one´s assigned gender”), without conceptualising an 
inherent degree of psychopathology.[26] Additionally, chromosomal variations and/or diverse sex 
developments (DSD) are no longer listed as exclusion criteria of GIC/GD.[26] Furthermore, both 




adolescents/adults respectively.[1, 26] Therefore, HCPs should know about the current diagnostic 
criteria and their implications (e. g., inclusion of genders that are beyond the gender binary, focus 
on GIC/GD, not on the identity of the person concerned), especially in countries where a referral 
from a mental health professional is needed for access to hormonal and/or surgical treatment. 
Values 
The evidence regarding the best assessment process for gender diverse children and adolescents is 
limited. Evidence regarding the prevalence of mental health problems in this population and the 
positive impact of GAMIs on mental health, quality of life and fertility is convincing. In case 
GAMIs are indicated, adolescents and their parents should be informed on the effect on their future 
sexual and reproductive health so they can reach an informed decision. Legally, in many European 
countries, adolescents cannot provide informed consent before age of majority and they need their 
parents for medical decision making.[27] However, in some member states, minors are capable of 
giving their consent and make their independent medical decisions at a certain age, or there is no 
fixed minimum age requirement for consent to medical treatments and each situation is treated 
individually depending on the maturity of the child.[27] From a psychological perspective we 
advise that trans adolescents are capable of making an independent informed medical decision 
while weighting the pros and cons of GAMI. As long as the adolescent lives in a family 
constellation, supporting the parents or other caretakers in providing a safe and supporting living 
situation is another preferred prerequisite.  
Remarks 
Clinicians working with gender diverse children and adolescents should have adequate knowledge 
and training or access to appropriate supervision. Assessment should take into consideration the 
evidence of a positive effect on mental health following social and psychological support and/or 





Assessment of trans adults 
Statements 
13. We advise that HCPs working with trans people should inform trans adults seeking GAMI 
of its effect and assess the capacity of the individual to reach an informed consent regarding 
GAMI. 
14. We advise that, in view of the strong evidence regarding the high levels of mental health 
problems in adults presenting at trans health services, particularly in those not on hormone 
treatment, HCPs whose role is informing and assessing the capacity to consent for GAMI 
in trans people wishing these interventions should have expertise in mental health in order 
to be able to identify those requiring further support from mental health professionals to 
allow for the best possible outcome of GAMI. 
15. We advise that HCPs whose role is informing and assessing the capacity to consent for 
GAMI in trans people wishing these interventions, should explore resilience and social 
support, in view of its association with health-related quality of life and psychological 
wellbeing. 
16. We advise that HCPs whose role is informing and assessing the capacity to consent for 
GAMI in trans people wishing these interventions, should inform clients about the effect 
that GAMIs (hormones as well as surgical) may have on sexual health and fertility. 
17. In countries requiring an assessment process including a clinical diagnosis in order to access 
Gender Affirming Medical Intervention (GAMI), we advise that HCPs assessing trans 




HCPs working with trans adults should assess the individual´s capacity to consent to GAMI.[28] 
In spite of the lack of evidence as to the best assessment process to follow, professionals working 
with the trans population should avoid being seen as gatekeepers.[29, 30] The role of the HCP will 




Along with the increasing prevalence of non-binary trans adults, the clinical characteristics of GIC 
can be very different from individual to individual.[2] Additionally, differences with regard to their 
treatment wishes across trans people identifying as male or female and non-binary trans people 
(identifying as genderqueer, agender, non-binary, etc.) seem to be important.[31, 32]  
In addition, professionals should be able to identify those who may present with mental health 
problems, not in order to stop the initiation of GAMI, but with the aim of increasing resilience and 
support achieving the best possible outcome of GAMI. The HCP may not be a mental health 
professional but they should have expertise in mental health in order to identify those who may 
require the input of a mental health professional.[2, 33] This is due to the evidence regarding the 
existence of higher levels of mental health problems, particularly depression,[34, 35] anxiety,[35, 
36] suicidality and self-harm,[37] among people attending trans health services (pre-hormone 
treatment) when compared to the cisgender population.[38] Mental health problems are predicted 
by not being on hormone treatment,[38, 39] having poor social support,[39, 40] and lack of 
resilience.[41] 
An important discussion to have with those seeking GAMI is the effect of treatment on sexual 
health and fertility. Few studies have explored the quality of sexual life in the trans population post 
GAMI. Sexual function, sexual desire and frequency of sexual activity, but also sexual satisfaction 
and pleasure can change after GAMI.[42, 43] Although the quality of sexual life improves post 
GAMI, research has demonstrated that it does not reach the levels of cisgender people.[44] But 
even if sexual function is impaired, the majority of participants report that they are more satisfied 
with their sexual life post-operatively.[45] This is particularly the case for trans AFAB people.[44, 
46] There are significant gaps in the literature regarding sexual satisfaction and sexual health, with 
most studies using small convenience samples that do not allow for generalisation. In addition, 
most substantial literature focusses on sexual functioning only, and not on sexual satisfaction. 
Lastly, many studies are limited by the lack of validated measures.[42, 43] Similarly, GAMI will 
also affect fertility.[47] Therefore, as part of the assessment process HCPs whose role is informing 
and assessing the capacity to consent for GAMI in trans people wishing these interventions should 
inform trans people about the effects that GAMI may have on their sexual function and fertility. 
Today´s trans health care is coordinated best in a multimodal concept between community-based 
self-help, mental health counselling and/or treatment and various transition-related somatic 




As gender identity is very personal and only the individual knows this, it can be argued as to 
whether a professional is able to assess it.[4, 48] As a consequence, HCPs working in trans health 
services may not assess the individual’s gender identity but their ability to understand the role of 
GAMI and their capacity to consent to treatment. Decisions on the necessity and sequence of 
interventions should be made in a participatory manner in the sense of agreement between 
treatment seekers and HCPs. In order to ensure individual trans health care in the long term, the 
therapeutic relationship should take into account both the body knowledge and self-determination 
of trans persons as well as the clinical expertise of HCPs.  
As for gender diverse children and adolescents (see above), HCPs should know about the current 
diagnostic criteria and their implications (e. g., inclusion of genders that are beyond the gender 
binary, focus on GIC/GD, not on the identity of the person concerned), especially in countries 
where a referral from a mental health professional is needed for access to hormonal and/or surgical 
treatment.  
Values 
The evidence regarding the best assessment process is limited. However, evidence regarding the 
positive effect of GAMI on mental health, quality of life, suggests that professionals involved in 
the assessment of adults with a trans identity should have experience in trans health and be able to 
recognise those requiring further input of mental health professionals. The existence of a mental 
health problem should not be a reason not to commence of GAMI, unless the capacity to consent 
for this treatment is affected. The process for the initiation of GAMI should primarily include 
providing information to the person as to the effect of GAMI in their life, and to assess the capacity 
for decision making of the individual. The assessor should also explore factors affecting quality of 
life such as mental health problems, support systems and resilience as this may affect the outcome 
of GAMI. 
Remarks 
Previous findings on the outcome of multimodal treatment date from the classic treatment paradigm 
of binary transgender people, which excluded non-binary trans people.[49-51] Therefore, follow-




and treatment reflected by the changes in diagnostic criteria from ICD-10 to ICD-11 actually leads 
to an improved health care for trans people. Standards regarding the assessment of trans people 
seeking GAMI that are evidence based are needed. Clinicians working in this field should have 
adequate knowledge, training and access to appropriate supervision. Assessment should take into 
consideration the evidence of a positive effect on wellbeing and mental health following hormonal 
treatment and the effect of withdrawing treatment in suicidality.  
Hormone therapy in trans AFAB people  
Statements 
18. We advise initiating pubertal hormone suppression in trans adolescents, when gender 
incongruence or nonconformity is assessed, interfering psycho-social difficulties are 
addressed if possible, and after they show their first pubertal changes (Tanner stage G2) 
and when they have sufficient capacity to give informed consent. 
19. We advise in adolescents desiring masculinising hormone treatment, when they have 
sufficient capacity to give informed consent, puberty induction with testosterone, often 
using a gradually increasing dose schedule.  
20. We advise that before initiation of Gonadotropin-releasing hormone analogs (GnRHa) or 
progestogen and/or testosterone the hormone-prescribing physician should screen for 
conditions that may worsen with the start of treatment. 
21. If masculinisation is desired, we advise testosterone therapy with monitoring of serum sex 
steroid levels and signs of virilisation. 
22. We advise the hormone-prescribing physician discusses the effects and possible adverse 
health effects of GnRHa, progestogen and/or testosterone treatment, including fertility 
preservation options, based on the person’s goals prior to any hormonal intervention. 
23. We advise informing trans subjects on the expected changes upon GnRHa, progestogen 
and/or testosterone initiation on its effect on body satisfaction, on sexual function (desire 
and activity), and considering the role that factors such as relationship status and possible 





Table 2:  
 Mode of administration Type Dosage Frequency 


















Oral  Testosterone 
undecanoate 


















If desired, trans adolescents usually start with GnRHa to inhibit female pubertal development, such 
as breast formation and menses, after they show their first pubertal changes (Tanner stage G2) and 
when they have sufficient capacity to give informed consent and interfering psycho-social 
difficulties are addressed, acknowledging that in many occasions they may not be resolved which 
should not affect the decision to initiate GnRHa.[52] A male pubertal induction is obtained using 
an increasing dose of testosterone.[3] Late adolescents often start testosterone ester at 75 mg 




GnRHa are advised to be continued at least until the maintenance dosage of testosterone is reached 
and to be continued until gonadectomy. In late-pubertal trans AFAB people menses can be 
suppressed using a progestational agent. GnRHa treatment may induce adverse effects on fertility 
and bone mineralisation, and effects on brain development remain unknown.[3] 
Trans men and non-binary AFAB people desiring masculinisation often opt for testosterone therapy 
with the aim to change their physical appearance to better match their gender identity. This may 
range from a more androgynous presentation to maximal virilisation.[3] Testosterone therapy that 
is initiated and monitored by a medical professional rarely leads to adverse events.[53] Before 
initiation of testosterone the hormone-prescribing physician needs to screen for conditions that may 
worsen with the start of virilising treatment, such as polycythaemia, sleep apnoea, deep vein 
thrombosis, pulmonary embolism, or untreated arterial hypertension. Absolute contraindications 
for testosterone therapy are (desired) pregnancy or lactation. If hormone therapy is contraindicated 
due to serious health conditions, access to non-hormonal medical interventions should be 
considered.[3] 
The preferred options for GAMI and monitoring in trans AFAB people have been summarised 
recently.[3] Often, the principles of hormone replacement therapy in hypogonadism with the aim 
to reach cisgender male testosterone levels are followed. If oophorectomy was performed, 
testosterone treatment is usually continued lifelong to avoid symptoms of hypogonadism, such as 
vasomotor symptoms and osteoporosis. If induction of amenorrhea is desired and does not occur 
with testosterone treatment alone, the addition of a progestational agent or GnRHa may be 
considered.[54] If hystero-oophorectomy was performed, this additional medication can be 
stopped. Laboratory monitoring of sex steroid levels and haematocrit is advised every three months 
in the first year, and once or twice yearly thereafter.[3] As many trans people have a desire for 
parenthood, reproductive options should be addressed by the health care providers at each stage of 
the gender affirming process. It is advised to preserve oocytes, ovarian tissue, or embryos before 
the initiation of gender affirmation therapies, if a genetically related parental desire exists, to avoid 
emotional difficulties when interrupting testosterone therapy in order to preserve germ cells.[55] 
Masculinising effects of testosterone treatment may include lowering of the voice, interruption of 
menses (if still present), appearance of male-pattern facial and body hair or male pattern baldness, 
increased prevalence and severity of acne, clitoral enlargement, increased muscle mass and strength 




subcutaneous fat, unless physical activity is increased. Clitoral growth has been described up to 
3.19 +/- 0.54 cm (+ 60%) after 3 months of testosterone treatment, and to 3.83 +/- 0.42 cm after 
two years of testosterone treatment.[56] Longer follow-up data are currently not available. Vaginal 
and cervical atrophy may lead to vaginal dryness, itching and painful penetration, for which over-
the-counter lubricants may be helpful. If cervical tissue is present, and if mastectomy was not 
performed, monitoring is recommended as in cisgender females.  
The literature on sexual functioning in the trans people desiring masculinisation is scarce and 
cannot be generalised, given the diversity within this group.[43] Therefore they should need to be 
evaluated in this domain according to many variables, such as e.g. the use of testosterone treatment, 
and modalities of genital surgery. The role of having a partner or presence of mental health 
symptomatology on sexual function should also not be underestimated.[57] A higher sexual desire 
in trans AFAB people who had recently started testosterone therapy was described.[46] Other 
studies noted an increase in sexual desire, fantasies, arousal and frequency of masturbation after 
one year of testosterone therapy.[58] Also, more sexual satisfaction, more sexual excitement, more 
easily reaching orgasm[45], and mostly (70%) an increase in sexual desire have been described in 
longer-term follow-up.[42, 46, 59] 
Safety 
Currently, there is no evidence for an increase in short and midterm cardiovascular adverse 
outcomes in trans people on testosterone treatment.[60-62] Data on older trans AFAB people are 
scarce but statements based on clinical experience are in favour of continuing testosterone.[60] As 
for independent cardiac risk factors, the decrease in high-density lipoprotein cholesterol, and 
increase in triglycerides and low-density lipoprotein cholesterol have been shown.[61] Haematocrit 
increases in the first year (+ 4.4 – 17.6% range), stabilising afterwards, within the reference range 
for cisgender men and rarely inducing clinically significant erythrocytosis.[63] Thromboembolic 
events are also reported to be rare.[64] Increase in insulin resistance or hepatotoxicity are not 
anticipated with parenteral or transdermal testosterone.[3] There is also no decrease in bone density 
to be expected,[65] even though there are very limited data on the risk of osteoporotic fractures. 
Osteoporosis screening should be performed especially in those who stop testosterone treatment 
after gonadectomy, or in those with limited compliance with therapy or with other risks for bone 




summarised: one vaginal, one cervical, seven breast, three ovarian and one endometrial cancers 
have been described to date.[66]  
Updated legislation in many European countries have omitted the need for gonadectomy for legal 
gender affirmation, so that the number of trans AFAB people who do not choose hystero-
oophorectomy is expected to increase.[67] Cervical smears are reported to be less frequently 
performed in trans AFAB people compared to cisgender women.[68] Large-scale prospective 
studies will be needed to evaluate the risk of trans AFAB people on testosterone treatment who did 
not undergo mastectomy or hystero-oophorectomy. Professionals should adhere to the established 
screening protocols based on the anatomical situation. 
Values  
In adolescent transgender care, puberty suppression has become an important element, even if long-
term success is not well-documented so far. However, denying medical intervention is potentially 
harmful. 
Knowledge of the short and midterm effects of testosterone in trans AFAB people shows rarely 
serious adverse events leading to interruption of treatment. In addition, serious adverse events 
leading to interruption of treatment are rarely encountered, if guided by a hormone-prescribing 
physician.  
Remarks 
The information on sexual function and satisfaction in trans AFAB people is quite limited, but most 
of the available literature points towards an improvement in sexual desire, activity, and satisfaction 
with testosterone treatment.  
This information is based on convenience samples of trans AFAB people who underwent genital 
surgery. There is a lack of literature on the effect of hormonal therapy in non-binary population or 




Hormone therapy in trans AMAB people  
Statements 
24. We advise initiating pubertal hormone suppression in trans adolescents, when gender 
incongruence or nonconformity is assessed, interfering psycho-social difficulties are 
addressed if possible, and after they show their first pubertal changes (Tanner stage G2) 
and when they have sufficient capacity to give informed consent. 
25. We advise in adolescents desiring feminising hormone treatment, when they have sufficient 
capacity to give informed consent, puberty induction with 17beta-estradiol, often using a 
gradually increasing dose schedule. 
26. We advise that before initiation of GnRHa or anti-androgens and/or estrogens treatment the 
hormone-prescribing physician needs to screen for conditions that may worsen with the 
start of treatment. 
27. If feminisation is desired, we advise estrogens and/or anti-androgen therapy with 
monitoring of serum sex steroid levels and signs of feminisation. 
28. We advise the hormone-prescribing physician discusses the effects and possible adverse 
health effects of GnRHa, anti-androgens, and/or estrogen treatment, including fertility 
preservation options and consequences for genital surgery, based on the person’s goals prior 
to any hormonal intervention. 
29. We advise informing trans clients on the expected changes upon GnRHa, estrogen and/or 
anti-androgen initiation and its effect on body satisfaction, sexual desire and activity, and 
considering the role factors such as relationship status and possible surgical interventions 
can play.  
Evidence 
Table 2  








Estrogen Oral Estradiol (17 beta-
estradiol valerate) 




Estradiol valerate  5-30mg  Every 1-2 
weeks 
Estradiol cypionate 2-10 mg Every week 




Estradiol gel 1,5 mg Once or twice 
daily 








Intramuscular  Triptorelin 11.23 mg 3-Monthly 
Intramuscular or 
subcutaneous 
Triptorelin 3.75 mg Monthly 
 
If desired, trans adolescents can start GnRHa when Tanner stage is over G2 to inhibit male pubertal 
development and when they have sufficient capacity to give informed consent and interfering 
psycho-social difficulties are addressed, acknowledging that in many occasions they may not be 
resolved which should not affect the decision to initiate GnRHa.[56] A female pubertal induction 
is obtained using increasing dose of estrogens (usually 17-beta estradiol).[56] GnRHa should be 
continued at least until the maintenance dosage of estradiol is reached, and is advised to be 
continued until gonadectomy. In late-pubertal trans AMAB people endogenous androgen 
production can be suppressed using antiandrogens such as cyproterone acetate (CPA).[3] 
Some trans women and non-binary individuals AMAB may seek hormonal treatment in order to 
make their body more congruent with their gender identity. Antiandrogen and/or estrogen treatment 
initiated and monitored by an experienced medical professional rarely leads to adverse events.[54] 
Before starting treatment, the treating clinician should evaluate and address conditions that can be 
exacerbated by this treatment, such as thromboembolic diseases, breast cancer, 
macroprolactinoma, coronary artery disease, cerebrovascular disease, cholelithiasis, and 
hypertriglyceridemia.[3] If hormone therapy is contraindicated due to serious health conditions, 




In order to induce (more) feminine secondary sex characteristics and/or to reduce the masculine 
ones, estrogens and/or anti-androgens can be used. The debate on the use of progesterone is 
ongoing, caused by a lack of data.[3] A wide range of estrogenic compounds exists, of which 
17beta-estradiol (oral 2-6 mg/d or transdermal) represents the treatment of choice. Estrogen dosage 
should be adjusted in order to maintain serum estradiol at the level for premenopausal females 
(100-200 pg/ml), although timing of treatment intake may affect blood concentrations. The most 
commonly antiandrogen used drug in Europe is CPA (oral 10 to 50 mg, once daily), a progestin 
with antiandrogenic properties. GnRHa are also effective in reducing testosterone levels with a low 
risk of adverse effects.[3] 
Cessation of tobacco use should be strongly recommended to avoid increased risk of 
thromboembolism and cardiovascular complications.[3] Traditionally, physicians advise estrogens 
should be stopped some weeks before any elective surgical intervention (including gender-
affirming surgery), and can be resumed once the person is fully mobilised.[3] However, practices 
are changing based on emerging literature.[69] After gonadectomy, estrogen treatment should be 
continued, in order to avoid the signs and symptoms associated with hypogonadism and to avoid 
osteoporosis. There is no consensus on whether hormonal treatment has to be stopped when trans 
women and non-binary individuals AMAB get older, mirroring the post-menopausal milieu.  
Many persons seeking feminisation are interested in using their own cryopreserved sperm to fulfil 
a future child wish[70]; thus fertility preservation techniques should be discussed and offered 
before starting hormone treatment.[55] Indeed, sperm cryopreservation, surgical sperm extraction 
and testicular tissue cryopreservation can be proposed. 
The most studied effect of feminising hormonal treatment is represented by breast development, 
which seems to be the only physical modification significantly correlated with the reduction of 
body dissatisfaction in trans AMAB people.[71] However, less than 20% of trans AMAB people 
reach a Tanner breast stage 4-5 after 2 years of treatment,[71] explaining why 50-60% seek 
augmentation mammoplasty.[72] Testis volume decreases by 40% after one year of therapy, 
making it easier to hide genitals and, thus, alleviating the perceived psychological distress.[71] 
Changes in fat distribution have been reported, with a decrease of lean body mass and an increase 
of subcutaneous body fat.[63] Hormonal treatment also induces a reduction in facial and body hair, 
as well as a decreased oiliness of skin.[71, 73] Complete removal of male sexual hair requires 




A decrease in sexual desire, spontaneous erections and male sexual dysfunction, often desired, are 
usually observed within 1-3 months after starting hormonal treatment.[3] According to a recent 
study, having a partner, being on hormone treatment, and having undergone some breast surgery 
have been associated with a better subjective perception of sexuality.[57] However, despite high 
rates of trans people declaring that they are dissatisfied with their sexual life before GAMIs,[57] 
only few studies have investigated sexual functioning and satisfaction in trans AMAB people and 
are mostly focused on genital surgery outcomes.[2, 42, 45, 57, 59, 75, 76] Indeed, studies 
evaluating the effect of hormonal intervention on sexual health, desire and arousability, and 
satisfaction are few and show contradictory results.[46, 59, 77, 78]  
Safety 
Among the possible adverse outcomes of hormonal treatment in trans AMAB people, a specific 
area of concern is represented by cardiovascular disease. According to a recent meta-analysis 
including 3231 trans AMAB people with a follow-up range from 3 months to 41 years, only a 
significant increase in triglycerides was observed during hormonal treatment.[61] Regarding the 
incidence of acute cardiovascular events, the largest available cohort study showed higher rates of 
venous thromboembolism and, to a lesser extent, ischemic stroke in trans AMAB people compared 
to cisgender men and women.[64] In addition, myocardial infarction rates were greater among trans 
AMAB people than in matched cisgender women, but similar to those observed among cisgender 
men. However, given the low quality of evidence due to the methodological limitations of the 
included studies, and heterogeneity of treatment, further research is needed to better clarify the 
cardiovascular effects of hormone therapy in trans AMAB people.  
An increase in lumbar spine bone mineral density has been reported with hormonal treatment in 
trans AMAB people, with a low rate of fractures.[65, 79] The prevalence of hormone sensitive 
cancers seems to be low among trans AMAB people during hormonal treatment.[66] 
Values  
Even if so far long-term success is not well-documented in adolescent transgender care, puberty 
suppression has become an important element. Denying medical intervention may be potentially 




effects of not receiving treatment when requested outweigh the potential risks of this treatment. In 
addition, serious adverse events leading to interruption of treatment are rarely encountered, if 
guided by a hormone-prescribing physician.  
Remarks 
To date, only a limited number of studies have investigated sexual satisfaction in trans AMAB 
persons and are mostly focused only on sexual function and satisfaction after genital affirming 
surgery. Studies specifically focused on non-binary individuals or on trans women who did not 
undergo genital surgery are missing.  
Sexual functioning and satisfaction in relation to surgical treatment in trans 
people 
Statements 
30. We advise HCPs should be aware of potential sexual problems during all surgical phases 
of treatment. 
31. We advise that regardless of surgical pathways, HCPs should be aware of diversity in sexual 
practices in trans people. 
32. We advise that surgeons performing Gender Affirming Surgery (GAS) collaborate with 
sexologists with knowledge and experience with trans people, if available.  
Evidence 
Gender Affirming Surgery (GAS) is an umbrella term for a variety of surgical procedures.[80] It 
is important to know that trans people may or may not follow a standard linear progression to 
hormones and then surgical procedures.[81] They may not choose surgical interventions for several 
reasons, including sexual motivations.[32] Surgeons interested in GAS are recommended in 
anticipation of a probably more liberal approach for the upcoming SOC8, to get acquainted with 




version 7 (SOC7) from the World Professional Association for Transgender Health (WPATH) 
where all details can be found about the multidisciplinary aspect of care and timing of surgery.[2] 
Medical contraindications are assessed by the responsible surgeon and anaesthesiologist who 
should maintain safety criteria according to American Surgical Association (ASA). The trans 
person should be well informed on the negative effects of smoking and/or a body mass index (BMI) 
of less than 18 and more than 30 kg/m2.[82-84] 
Surgical procedures for feminising GAS are orchiectomy, vulvoplasty (no vaginal cavity is made), 
vulvo-vaginoplasty, breast augmentation, voice surgery, chondrolanryngoplasty and facial 
feminisation. In vulvo-vaginoplasty the inner lining is made with penile skin, skin grafts, penile 
skin combined with skin grafts or a bowel segment.[85, 86] The base of the penis and the 
perineoscrotal region that will form vaginal inner lining or will be placed around the clitoris should 
be depilated permanently. Otherwise hair growth within the neo-vagina can cause discharge or 
odour. 
Surgical procedures for masculinising GAS are mastectomy, removal of female sexual organs, 
metaidoioplasty and phalloplasty. Urethral lengthening, optional in both metaidoioplasty and 
phalloplasty, entails a higher complication risk. Urethral lengthening is often done with skin of the 
forearm. To prevent hair growth inside the urethra, depilation is advised, because discharge and 
voiding problems can occur. If desired, a colpectomy may need to precede in some centres.[87] 
Removal of female sexual organs can be done individually or all at once (hysterectomy, 
ovariectomy and colpectomy). If a colpectomy will be performed, a hysterectomy must also be 
performed. The ovaries may remain in situ, upon request.  
Voiding problems can occur in genital GAS, implying it is advisable to co-operate with an urologist 
when offering care for trans individuals, so consultation is possible when needed before, during 
surgery and after surgery. In an ideal setting, collaboration with pelvic physiotherapists is advisable 
for voiding problems after GAS and accessibility problems of the vagina after a vaginoplasty, 
during dilation or sexual contact. 
The potential sexual problems trans people encounter may occur in all phases of surgical treatment. 
Collaboration with a sexologist with knowledge and experience with trans people is recommended. 
Overall results lean towards favourable sexual outcomes after genital surgeries in trans people, 




The majority of post-surgical AMAB people report satisfaction with their sexual life post-
operatively.[45] 
In the majority of trans AFAB people with metoidioplasty, voiding while standing as well as 
penetrative sexual intercourse is not reached.[88] However, regarding sexual satisfaction, patient-
reported satisfaction with sexual function and aesthetic outcome is very high (up to 100%), and no 
problems with sexual arousal, masturbation, or orgasms were reported.[89, 90]  
In trans AFAB people with phalloplasty, sexual activity was higher (masturbation and with 
partner), and they used their genitals more frequently during sex compared with before surgery 
(31-78%).[91] Sexual expectations were more frequently met in the group with an erection 
prosthesis (compared to those without), but pain during intercourse was more often reported.[45]  
However, in most of the studies that were selected in the review period, the overall data were 
limited, heterogeneous, of very low quality, and validated measurement tools were missing. There 
is a strong need for future research, which should focus on the development of validated tools to 
assess postsurgical sexual outcomes. 
Because of the lack of psychosexual education or guidance during the hormonal and post-operative 
phase, combined with low sexual experience, most trans people lack knowledge of the new 
anatomy, ways of sexual stimulation and getting aroused and what changes can be expected. Pain 
with penetration can occur after genital feminisation and masculinisation, and it is important to 
explore the right cause of the pain before planning a hastily surgical correction.[92-94] Phantom 
pain after vaginoplasty is one of the lesser known problems and should be taken seriously.[95]  
Values  
The ESSM emphasises the importance to share the responsibility in the decision making process 
towards surgery together with all involved HCPs and to keep well written documentation of the 
met criteria for a specific surgical treatment. 
Remarks 
To date, validated tools helping the choice for interventions for trans people are lacking. Sexual 
outcomes are mostly postsurgical while other phases are underexposed. There is need for future 





We presented with this document an up-to-date ESSM position statement on trans health care, with 
attention for sexual functioning and satisfaction. The data on trans health care are rapidly emerging, 
and all suggestions and statements are based on the currently available data, acknowledging this is 
a rapidly changing field.  
Limitations 
The primary aim of the position statement was to formulate clinical consensus statements for 
European clinicians working in the field of transgender health in view of the recent change in the 
clinical diagnosis use in transgender health in the ICD-11.[1] The paper also aims to provide 
recommendations regarding sexual health care of trans people, although due to the limited amount 
of publications the recommendations that can be provided in this area are minimal. Furthermore, 
this position paper does not aim to provide detailed clinical guidelines for professionals such as 
those from the WPATH or the Endocrine Society.[2, 3] 
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